Hereditary Papillary Renal Carcinoma


To claim CME please visit this link: http://bit.ly/3YQqiXv
.75 CME | MOC
In this case based discussion, discover recent clinical trial findings on checkpoint inhibitors and VEGFR-directed therapies that can inform personalized care plans for patients with renal cell carcinoma (RCC). Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, will provide expert perspectives on the myriad of novel therapeutic options for advanced RCC. Start the activity now!
STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their knowledge of RCC pathophysiology and the benefits and risks of novel therapies. In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Eric Jonasch, MD, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, imparts expert perspectives and details the latest treatment options for advanced RCC.
TARGET AUDIENCE
Military, academic, and private practice urologists, nurse practitioners, and physician assistants involved in the treatment of patients with renal cell carcinoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Discuss the immunogenicity of RCC and the implications for the treatment of advanced disease
Assess criteria for risk stratification of patients with advanced RCC
Evaluate recent clinical trial findings on novel treatment strategies for advanced RCC with checkpoint inhibitors and VEGFR-directed therapies


Dr. Farzanna Haffizulla interviews Ramaprasad Srinivasan MD, PhD on Papillary Renal Cell Carcinoma
Video originally published on PracticeUpdate.com on 02/26/2018 -- https://www.practiceupdate.com..../content/updates-on-
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Register for PracticeUpdate for free at https://www.practiceupdate.com/welcome


The world's largest, most respected, and fully accredited kidney cancer charity presents information of interest to patients seeking a clinical trial for treatment of papillary kidney cancer. Interested in learning more about how to join a clinical trial? See: http://emergingmed.com/partners/kca/


https://word2speech.com/medical/
Papillary renal cell carcinoma
Papillary renal cell carcinoma: A type of kidney cancer that accounts for 15 to 20% of renal carcinomas. It occurs in both sporadic and familial forms. Hereditary papillary renal carcinoma is characterized by the development of multiple papillary tumors in both kidneys. The pattern of inheritance is consistent with autosomal dominant transmission with reduced penetrance. The disorder is distinct from other forms of inherited kidney cancer.
How to pronounce, definition of, audio dictionary, medical dictionary


This entry is part one in a series of instructional videos detailing a meta-analysis on eight different human gene expression studies looking at papillary renal cell carcinoma (pRCC). In this installment, I give some background on kidney cancer and detail the different types and subgroups identified in papillary renal cell carcinoma. (I never claimed to be a urologic oncologist, so please forgive any errors in my descriptions of the condition). Please subscribe to this YouTube channel or sign up to my blog (www.bioinfosolutions.com/blog/) to receive notifications on when the next video in the series is posted.
Inspiration for this meta-analysis on papillary kidney cancer came from an upcoming ‘Hackathon’ in May (https://sv.ai/papillary-renal-cell-carcinoma/) that brings together researchers, engineers and computer scientists to try to tackle challenging problems in life sciences. This year they are focusing on papillary renal-cell carcinoma type 1 (p1RCC), a disease that accounts for between 15 to 20% of all kidney cancers. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist.
Special thanks goes out to the biotech companies Illumina (Correlation Engine and Cohort Analyzer), Partek Inc. (Partek Genomics Suite) and Elsevier (Pathway Studio) for donating their platforms and providing technical assistance for this bioinformatics series.